Tanya S. Ramey, MD, PhD
Article
Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder
February 5, 2015
Here, review results from a post hoc analysis that evaluated the tolerability of long-term desvenlafaxine for major depressive disorder at discontinuation using a taper regimen compared with abrupt discontinuation.Â
